Study of Weekly Cabazitaxel for Advanced Prostate Cancer

NCT01518283 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG: Cabazitaxel 10 mg/m2

Sponsor

Spanish Oncology Genito-Urinary Group